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Identification of novel, therapy-
responsive protein biomarkers 
in a mouse model of Duchenne 
muscular dystrophy by aptamer-
based serum proteomics
Anna M. L. Coenen-Stass1, Graham McClorey1, Raquel Manzano1, Corinne A. Betts1, 
Alison Blain2, Amer F. Saleh3,†, Michael J. Gait3, Hanns Lochmüller2, Matthew J. A. Wood1 & 
Thomas C. Roberts1,4
There is currently an urgent need for biomarkers that can be used to monitor the efficacy of 
experimental therapies for Duchenne Muscular Dystrophy (DMD) in clinical trials. Identification of 
novel protein biomarkers has been limited due to the massive complexity of the serum proteome and 
the presence of a small number of very highly abundant proteins. Here we have utilised an aptamer-
based proteomics approach to profile 1,129 proteins in the serum of wild-type and mdx (dystrophin 
deficient) mice. The serum levels of 96 proteins were found to be significantly altered (P < 0.001, 
q < 0.01) in mdx mice. Additionally, systemic treatment with a peptide-antisense oligonucleotide 
conjugate designed to induce Dmd exon skipping and recover dystrophin protein expression caused 
many of the differentially abundant serum proteins to be restored towards wild-type levels. Results 
for five leading candidate protein biomarkers (Pgam1, Tnni3, Camk2b, Cycs and Adamts5) were 
validated by ELISA in the mouse samples. Furthermore, ADAMTS5 was found to be significantly 
elevated in human DMD patient serum. This study has identified multiple novel, therapy-responsive 
protein biomarkers in the serum of the mdx mouse with potential utility in DMD patients.
Duchenne Muscular Dystrophy (DMD) is a lethal monogenic disorder and the most prevalent inher-
ited myopathy affecting children. Although currently incurable, many therapeutic strategies for DMD 
have been proposed. A highly promising approach is antisense oligonucleotide-mediated exon skipping, 
which aims to modulate splicing of the dystrophin gene (human: DMD, mouse: Dmd) so as to restore 
the translation reading frame which is disrupted by DMD-associated mutations. We have developed a 
second generation exon skipping technology called PPMO (peptide-phosphorodiamidate morpholino 
oligonucleotide) which induces exon skipping and dystrophin restoration at high levels in skeletal muscle 
and diaphragm, and at moderate levels in heart1,2. Clinical trials with first generation exon skipping com-
pounds (2′ -O-methyl RNA and naked PMO chemistry) have demonstrated both promise3,4 and some 
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disappointment5. One of the difficulties in assessing the effectiveness of these experimental therapies has 
been finding appropriate outcome measures of clinical benefit.
Methods for assessing the restoration of dystrophin protein in treated patients are currently restricted 
to analyses of muscle biopsies (e.g. western blot and immunofluorescence microscopy). Conceptually, the 
usefulness of muscle biopsies is limited, given that only a tiny fraction of a single muscle is assayed, using 
only semi-quantitative measures. Muscle biopsy is also highly invasive and painful for patients, meaning 
that serial measurements are not ethically permissible or practical. Similarly, the six minute walk test, 
in which the distance walked by a patient within 6 minutes is recorded before and after treatment6, also 
has limitations including high inter-patient variability and an unclear relationship to disease natural 
history. The usefulness of this test may also be limited by the patient’s compliance with the protocol. 
Furthermore, some patients lose ambulation as a result of the natural progression of the disease, meaning 
that they are unable to perform the test. An alternative approach has been to use a panel of functional 
outcome measures such as The North Star Ambulatory Assessment (NSAA) protocol7. However, NSAA 
is also only applicable to ambulant patients, thereby excluding those patients with the most severe disease 
manifestation.
Magnetic Resonance Imaging (MRI) is another method of monitoring pathology in DMD by reveal-
ing the extent of muscle degeneration (i.e. muscle wasting, fibrosis and deposition of adipose tissue) but 
does not provide a direct read-out of muscle function per se. Additionally, this approach is subject to 
a number of limitations such as high cost, low through-put and a requirement for specialist personnel 
trained in interpreting the MRI data. MRI is therefore less suitable for use in trials with large patient 
cohorts than clinical chemistry analysis.
Elevated serum creatine kinase (CK) is commonly used as a clinical chemistry biomarker for neu-
romuscular disorders, and DMD in particular. However, serum CK levels vary widely in healthy indi-
viduals and may also be elevated in asymptomatic individuals. In addition, serum CK is sensitive to a 
number of factors such as exercise, age, race, and pharmacological interventions (e.g. statin use). CK 
is also considered a non-specific marker of muscle damage as it is elevated after myocardial infarction, 
myocarditis, myositis, rhabdomyolysis and rhabdomyosarcoma8. While hyperCKemia is indicative of 
DMD-associated muscle damage, serum CK levels may decline in older patients with more advanced dis-
ease on account of reduced muscle mass9. Importantly, serum CK measurements do not always correlate 
with other read-outs of muscle pathology such as MRI, thus they are of limited value for monitoring the 
effectiveness of experimental therapies10.
Consequently, there is an urgent need for minimally-invasive biomarkers that can be used as outcome 
measures in pre-clinical studies and clinical trials for DMD therapeutics. Analysis of blood is frequently 
the first line of clinical investigation as it is simple, safe and provides insight into the physiology of 
the entire body. One source of possible biomarkers is circulating microRNAs11. We and others have 
shown that muscle-specific microRNAs are enriched in the serum of dystrophic animal models12–14 and 
in DMD patients15. However, protein-based biomarkers are perhaps preferable on account of the ease 
with which they can be integrated into existing clinical biochemistry workflows (i.e. measurement by 
Enzyme-Linked Immunosorbent Assay (ELISA) or standard colourimetric/turbidimetric assays).
The search for novel protein biomarkers entails the application of proteomics techniques to biofluids 
such as serum or plasma. Mass spectrometry techniques are by far the most commonly used methods 
of whole proteome analysis and recent developments have enabled the simultaneous measurement of 
over 10,000 proteins from cell culture lysates16 and over 3,000 proteins in dystrophic mouse muscle17. 
However, proteomic analysis of the serum/plasma proteome is complicated by the immense complexity 
of these biofluids. In principle, the circulation contains every possible protein in the body as it consists 
of both secreted proteins which exercise their functions in the extracellular space, and proteins derived 
from tissues that leak into the bloodstream following injury or stress. Furthermore, the composition of 
the circulating proteome is highly uneven, with a group of ~20 highly abundant proteins comprising 
~90% of the total protein (e.g. serum albumin, α 2-macroglobulin, immunoglobulins, fibrinogen etc.) 
Consequently, the majority of circulating proteins (including potential biomarkers) are typically much 
less abundant. Extracellular proteins span a concentration range of ~10 logs, meaning that detection of 
lowly abundant potential biomarker proteins is frequently masked by massively more abundant pro-
teins18. As a result of these difficulties, mass spectrometric methods generally perform poorly on complex 
protein mixtures derived from biofluids.
To overcome these challenges we have utilised an aptamer-based affinity purification methodology 
(SOMAscan) to analyse the serum proteome of wild-type, dystrophic and PPMO-treated mice. This 
technology enables the determination of protein concentrations for a specific set of targets independent 
of highly abundant serum proteins which confound mass spectrometry based analyses.
The use of genetically homogenous animal models is advantageous on account of low inter-animal 
variation. As a result, statistical power to detect differences is high despite relatively small sample sizes. 
Using this experimental approach we have identified multiple novel therapy-responsive protein biomark-
ers in murine serum. One of the most promising candidate biomarkers, ADAMTS5, was further vali-
dated in DMD patient serum.
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Results
Proteomic profiling of dystrophic serum by SOMAscan. To identify novel protein biomarkers for 
DMD we harvested serum from 14 week old C57, mdx and PPMO-treated mdx mice (n = 8). Treated 
mice were injected at 12 weeks of age with a single 12.5 mg/kg dose of Pip6a-PMO and harvested 2 
weeks later as described previously1,13. Dystrophin protein restoration in quadriceps femoris muscles of 
treated animals was confirmed by western blot, and the degree of Dmd exon 23 skipping determined by 
RT-qPCR (Supplementary Fig. S1a,b). Median Dmd protein expression in Pip6a-PMO-treated animals 
was 39% that of wild-type controls, which is comparable to levels observed in our previous studies1,13. 
Western blot and RT-qPCR data were strongly correlated (Supplementary Fig. S1c).
Serum protein abundance was profiled using the SOMAscan platform19, an affinity-capture based 
approach which consists of 1,129 SOMAmers (Slow Off-rate Modified Aptamers) designed to bind to 
human serum proteins (the majority of which exhibit reactivity, or predicted reactivity based on homol-
ogy, to their murine homologues). SOMAmer-protein complexes are precipitated and protein concen-
tration inferred by hybridising the SOMAmers to DNA micorarrays. To increase the dynamic range of 
analyte detection, the SOMAscan methodology utilises three dilutions of serum samples (0.5%, 2% and 
5% respectively) with a unique set of SOMAmer reagents used to detect target proteins at each dilution 
level19.
Applying this approach, we were able to detect all SOMAmer targets in all samples. One treated sam-
ple (T7) was excluded from the analysis as it did not pass quality control checks for biases in SOMAmer 
hybridization (Supplementary Fig. S2a). Probe hybridization was equivalent between all samples 
(Supplementary Fig. S2b) although median normalisation scale factors were slightly skewed in the mdx 
samples, suggesting an increase in total protein concentration in these samples (Supplementary Fig. S2c). 
This observation is similar to the increase in total RNA and total microRNA in dystrophic serum we have 
reported previously20. Experimental groups were clearly separated by unsupervised clustering analysis 
(Supplementary Fig. S3a) and principal component analysis (Supplementary Fig. S3b) suggesting that 
serum protein measurements can be utilised to distinguish dystrophic from healthy individuals.
Comparison of the C57 and mdx groups revealed 96 proteins with statistically significant changes in 
abundance (Mann-Whitney U test, FDR correction, P < 0.001, q < 0.01) of which 75 showed an increase 
and 21 a decrease in mdx sera. Highly differentially abundant proteins at each dilution level were visual-
ised by scatter plot (Fig. 1a). The majority of differentially abundant proteins were observed in the higher 
dilution samples (i.e. lower abundant proteins) with only LDHB (lactate dehydrogenase B) identified in 
the 0.5% dilution group (i.e. highly abundant proteins) (Fig. 1a). Proteins that were both highly differen-
tially expressed and highly statistically significant were identified by volcano plot (Fig. 1b).
When all three experimental groups were compared, 130 proteins were identified as statistically differ-
ent (Kruskal-Wallis one-way ANOVA, P < 0.001, q < 0.01) of which 104 were restored towards wild-type 
levels after PPMO treatment (73 proteins were more, and 31 less abundant in mdx sera respectively). 
Experimental groups were well separated by hierarchical clustering (Fig.  1c) and principal component 
analysis (Supplementary Fig. S4a). Substantial overlap was observed between the proteins found to be 
significant by Mann-Whitney U test and Kruskal-Wallis one-way ANOVA (Supplementary Fig. S4b).
A set of 21 proteins with increased and 2 with reduced serum abundance were identified as the most 
promising candidate DMD biomarkers based on the following criteria: (i) differentially abundant in mdx 
serum by > 2 fold, (ii) statistically significant (P < 0.01) as determined by both Kruskal-Wallis one-way 
ANOVA and Mann-Whitney U test, (iii) proteins which responded to treatment with Pip6a-PMO were 
prioritised (Fig. 2, Table 1). Response to therapy was defined as a shift in the mean protein abundance 
towards wild-type levels. Some proteins showed complete normalisation (i.e. CYCS, ADAMTS5, HTRA2 
and CAPN1), whereas the majority of proteins showed more modest restoration (i.e. MB, LDHB, FABP3, 
CAMK2B). Two proteins (TNNI2 and TPI1) that were among the most differentially abundant proteins 
in mdx sera displayed little or no response to therapy but were included based on their potential as 
diagnostic biomarkers.
This list contains a number of novel potential DMD biomarkers and some proteins which have been 
identified previously (i.e. MB, LDHB, FABP3, CYCS, TPI1 and THBS4)21–23. Interestingly, many of 
these proteins are associated with known pathophysiological features of DMD including muscle func-
tion (MB, TNNI2, TNNI3), metabolic dysregulation (PGAM1, LDHB, TPI1, FABP3), calcium metab-
olism (CAMK2A, CAMK2B, CAMK2C, CAPN1), and extracellular matrix remodelling/fibrogenesis 
(ADAMTS5, THBS4)24.
ELISA validation of candidate biomarkers in murine serum. Several of the identified proteins 
have previously been reported as being elevated in dystrophic serum or as biomarkers of tissue damage 
in general (Table 1). We therefore selected a subset of proteins with no known previous association with 
DMD (Pgam1, Tnni3, Camk2b, Capn1 and Adamts5) and Cycs (which showed a strong response to 
therapy) for validation by ELISA (Fig. 3). Murine CK-MM was also included given its importance as an 
established DMD biomarker, although it ranked poorly relative to the top candidate proteins as deter-
mined by SOMAscan (Fig. 2, Table 1). Capn1 protein was not detectable by ELISA. Protein abundance 
was found to be significantly elevated in mdx serum (P < 0.0001) for all remaining candidates except for 
Camk2b (P < 0.06). Pgam1, Tnni3 and Camk2b were enriched in mdx serum by 2.2–2.6 fold (relative to 
wild-type controls) but showed little or no restoration towards wild-type levels after PPMO treatment. 
www.nature.com/scientificreports/
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Clear shifts in protein abundance towards wild-type levels were observed for Adamts5, Cycs and CK-MM 
following PPMO treatment. The concentration of Cycs in mdx serum was increased by 11 fold in mdx 
serum and reduced to a 7 fold increase after exon-skipping treatment. Similarly, Adamts5 was enriched 
by 7.6 fold in mdx serum and restored to 2 fold after treatment. CK-MM levels were elevated by 4 fold 
in mdx serum and completely restored to wild-type mice levels following exon skipping therapy.
ADAMTS5 is elevated in DMD, BMD and FSHD patient serum. Based on the SOMAscan data 
and ELISA validation we selected ADAMTS5 and PGAM1 for further investigation. ADAMTS5 exhib-
ited the lowest P value in the SOMAscan screen (P = 0.000056) and profound restoration after therapy. 
Similarly, the ELISA data showed good normalisation after treatment with low inter-sample variation, 
thereby suggesting that ADAMTS5 may be useful as a biomarker for monitoring the response to therapy 
in DMD patients. The second lead candidate, PGAM1, showed only a mixed response to therapy but was 
the most elevated protein (136 fold) in mdx serum as determined by SOMAscan array.
Human-specific ELISAs for ADAMTS5 and PGAM1 were performed in DMD patient serum (n = 30) 
and compared with healthy controls (n = 18). Additionally, we also included serum from patients with 
Becker Muscular Dystrophy (BMD) (n = 30) and FacioScapuloHumeral muscular Dystrophy (FSHD) 
(n = 14). BMD is a dystrophinopathy with much milder symptoms than DMD25,26. In contrast, FSHD 
Figure 1. Identification of novel DMD biomarkers. Serum samples from C57, mdx and Pip6a-PMO-
treated mdx were analysed using the SOMAscan methodology. (a) Scatter plot of mean relative fluorescent 
units (RFU) for mdx vs C57 identifies differentially abundant proteins separated by dilution group.  
(b) Statistically significant (P < 0.01) protein changes in mdx serum were determined by Mann-Whitney 
U test and visualized by volcano plot. (c) Proteins with statistically significant changes when comparing 
between all three experimental groups (Kruskal-Wallis one-way ANOVA P < 0.001, q < 0.01) were analysed 
by hierarchical clustering. Red indicates more abundant proteins and blue indicates less abundant proteins. 
The scale bar represents the row z-score.
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is an autosomal dominant muscular dystrophy caused by contraction of the D4Z4 macrosatellite repeat 
leading to toxic DUX4 gain-of-function and therefore has a molecular pathogenesis that is distinct from 
DMD27. ADAMTS5 was significantly (P < 0.01) elevated in the serum of DMD patients by 3.4 fold rela-
tive to healthy controls (Fig. 4a). Similarly, ADAMTS5 was also elevated in BMD (P < 0.05) and FSHD 
(P < 0.01) patient serum (Fig. 4a). The mean of serum ADAMTS5 abundance was slightly lower in BMD 
patients relative to DMD although the median values were very similar. All experimental groups exhib-
ited high variability, with the FSHD patient cohort being the most variable. Receiver operating charac-
teristic (ROC) curve analysis showed that ADAMTS5 was similarly effective at discriminating between 
healthy and dystrophic individuals from each patient group (AUC ≥ 0.74, P < 0.01 in all cases) although 
the discrimination was marginally better for DMD (AUC = 0.78) (Fig.  4b). Consequently, ADAMTS5 
may be useful for diagnosing muscle pathology or monitoring the response to therapy in patients with 
established diagnoses, but is not capable of distinguishing between DMD, BMD and FSHD pathology. No 
correlations were observed between ADAMTS5 levels and age in the case of the DMD or FSHD cohorts, 
whereas a negative correlation was observed for BMD (Supplementary Fig. S5). In contrast, PGAM1 was 
not detectable in any of the human serum samples.
Figure 2. Top candidate disease biomarkers in dystrophic and exon skipping-treated serum. Plots 
of protein abundance data showing each individual biological replicate for the top 23 ranked candidate 
biomarkers identified by SOMAscan. Error bars indicate mean + /− SEM. Kruskal-Wallis one-way ANOVA 
P values and mdx vs C57 fold changes are indicated for each protein. q = 0.00822 for all proteins shown.
www.nature.com/scientificreports/
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Discussion
Here we have utilised an aptamer-based proteomic screening approach to identify a plethora of novel 
candidate biomarkers for DMD. We successfully identified well-described biomarkers of generic mus-
cle tissue damage (CK-MM, MB, LDHB, and FABP3)28–30 as being elevated in mdx sera (summarised 
in Table  1). Additionally, we also identified CYCS, TPI1 and THBS4 as being elevated in dystrophic 
serum, consistent with the findings of Hathout et al. utilising a mass spectrometry-based approach22 
(Supplementary Table S1). All of these proteins were restored towards wild-type levels following dystro-
phin restoration, supporting their usefulness for monitoring the effectiveness of therapeutic interventions 
in DMD patients. Results for Pgam1, Tnni3, Camk2b, Cycs, Adamts5 and CK-MM were further assessed 
by ELISA. The proteins identified in the present study can be classified into a number of groups: (1) 
muscle function (MB, TNNI2, TNNI3), (2) metabolic dysregulation (PGAM1, LDHB, TPI1, FABP3), (3) 
calcium metabolism (CAMK2A, CAMK2B, CAMK2C, CAPN1), (4) extracellular matrix remodelling/
fibrogenesis (ADAMTS5, THBS4), and (5) others. Interestingly, two proteins (TYMS and SFN) were less 
Entrez ID Name UniProt ID
Fold 
Change 
(mdx vs 
C57)
Dilution 
(%)
Restoration by 
PPMO Reference
PGAM1 Phosphoglycerate mutase 1 P18669 136 5 + + 
TNNI3 Troponin I, cardiac muscle P19429 53 5 + + + 37
MB Myoglobin P02144 15 2 + + 21,22,37
TNNI2 Troponin I, fast skeletal 
muscle P48788 14 5 + 37
LDHB L-lactate dehydrogenase B 
chain P07195 8.4 0.5 + + 23,37
FABP3 Fatty acid-binding protein, 
heart P05413 7.8 5 + + 22,37
TPI1 Triosephosphate isomerase P60174 5.7 2 - 22
CAMK2B Calcium/calmodulin-
dependent protein kinase type II 
subunit beta 
Q13554 5.3 5 + + 
CAMK2A Calcium/calmodulin-
dependent protein kinase type II 
subunit alpha
Q9UQM7 4.1 5 + + 37
ANP32B Acidic leucine-rich nuclear 
phosphoprotein 32 family member B Q92688 3.7 2 + + 37
CYCS Cytochrome c P99999 3.6 2 + + + 22
CAMK2D Calcium/calmodulin-
dependent protein kinase type II 
subunit delta
Q13557 3.6 5 + + 
PCNA Proliferating cell nuclear 
antigen P12004 3.3 5 + + 
HTRA2 Serine protease HTRA2, 
mitochondrial O43464 3.1 5 + + + 
ADAMTS5 A disintegrin 
and metalloproteinase with 
thrombospondin motifs 5
Q9UNA0 2.8 5 + + + 
PTPN11 Tyrosine-protein 
phosphatase non-receptor type 11 Q06124 2.8 5 + + 
LYN Tyrosine-protein kinase Lyn P07948 2.7 5 + + 
DUSP3 Dual specificity protein 
phosphatase 3 P51452 2.5 5 —
CAPN1 Calpain I P07384 P04632 2.4 2 + + + 
THBS4 Thrombospondin-4 P35443 2.2 2 + + 22
EDA2R Tumor necrosis factor 
receptor superfamily member 27 P35443 2.1 5 + + 
TYMS Thymidylate synthase P04818 − 2.7 5 + + 
SFN 14-3-3 protein sigma P31947 − 3.2 2 + + 
Table 1.  Top candidate serum protein biomarkers for DMD identified by SOMAscan. + + + restored to 
wild-type levels, + + restored towards wild-type levels, + inconsistent restoration towards wild-type levels 
between replicates, —not restored towards wild-type levels.
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abundant in dystrophic serum, which cannot be easily explained as the result of passive leakage from 
damaged muscle.
Previous studies have investigated serum protein abundance in human DMD patients and 
dystrophic animal models using mass spectrometry22,31,32, bead-based antibody arrays33 or more focused 
approaches34–36. A limitation of the present study is that only the predetermined 1,129 proteins (for which 
there are SOMAmer reagents available) could be measured. However, this is still a greater number than 
has been detected by mass spectrometry (335 proteins detected)22 or by antibody-based bead arrays (315 
target proteins)33. Notably, there were no SOMAmer probes targeted against many putative biomarker 
proteins identified in these studies (e.g. F13A1, FN1, TIMP1, MMP9, TNNT3, MYOM3), and so these 
were invisible to our study. Another potential limitation of our approach is that the SOMAmer target 
Figure 3. ELISA validation of candidate biomarkers. Five of the top candidate biomarker proteins were 
validated by ELISA using antibodies targeting the murine proteins. Murine CK-MM was included for 
comparison. Individual biological replicates are shown. Error bars indicate mean + /− SEM. One-way 
ANOVA P values and mdx vs C57 fold changes are indicated for each protein. Bonferroni post hoc test 
significance values are indicated as **P < 0.01, ***P < 0.001.
Figure 4. ADAMTS5 is elevated in DMD, BMD and FSHD patient serum. (a) ADAMTS5 abundance was 
measured by ELISA in serum samples from healthy control individuals (n = 18), DMD patients (n = 30), 
BMD patients (n = 30) and FSHD patients (n = 14). Data are shown as scatter plots showing individual 
replicates and box plots side-by-side. Error bars indicate mean + /− SEM. Box plots show median and 
interquartile range, whiskers represent the 10 to 90% range. Differences between groups were significant 
(P = 0.0023) as determined by one-way ANOVA. Bonferroni post hoc test significance values are indicated as 
**P < 0.01, *P < 0.05. (b) ROC curves for DMD, BMD and FSHD patients. AUC, Area Under the Curve.
www.nature.com/scientificreports/
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capture reagents were developed to bind to recombinant human proteins, and so interspecies differ-
ences in protein sequence may obscure important disease-associated changes. Similarly, cross-reactivity 
of SOMAmer reagents with proteins that are closely homologous with the target analyte may explain 
the discordant ELISA results for PGAM1 and CAPN1 (in these cases, it is possible that the SOMAmers 
cross-reacted with Pgam222 and the muscle-specific calpain isoform Capn3 respectively). Additionally, 
some proteins may exist as processed fragments in the circulation36, or may form protein complexes, 
meaning that their target epitopes are absent or concealed. Together, these factors may explain some of 
the minor discrepancies between the SOMAscan data and ELISA validation. Notably, during the prepa-
ration of this manuscript Hathout et al. reported a SOMAscan study in DMD patient sera with many 
findings consistent with those presented here37 (Table 1, Supplementary Table S1). In this study, serum 
samples from 93 DMD patients and 45 control individuals was analysed using the SOMAscan platform 
and 44 significantly changed proteins were identified. Among these, TNNI2, TINN3, FABP3, MB, LDHB, 
AN32B and CAMK2A were consistent with the present study, thus confirming the robustness of the tech-
nique across human and mice. In contrast to our study, ADAMTS5 was not identified as being increased 
in DMD patient serum. This highlights a limitation of biomarker discovery studies in outbred patient 
populations where differences in genetic background may obscure important findings.
Consistent with our SOMAscan data, the concentration of ADAMTS5 was also found to be increased 
in DMD patient sera, supporting its use as a clinical biomarker. However, elevated ADAMTS5 was 
also observed in BMD and FSHD patients suggesting that it may be a non-specific marker of muscle 
pathology. Interestingly, expression of ADAMTS5 was previously shown to be elevated in the muscle of 
FSHD patients38. Notably, potential serum protein biomarkers for FSHD were recently identified in an 
antibody-based screen, although ADAMTS5 was not included in the panel of antibodies tested39.
In conclusion, we have identified multiple novel protein biomarkers in a murine model of DMD, one 
of which was validated in DMD patient serum. Many of these putative biomarkers were restored towards 
wild-type levels following dystrophin exon skipping, suggesting that these may be useful for monitoring 
the response to experimental therapies in clinical trials. In addition, protein-based serum biomarkers 
have the advantage that they can be easily measured with ELISA assays in an automated fashion and are 
therefore suitable for screening large patient cohorts. Several of the identified proteins are involved in 
DMD-associated pathophysiological processes such as metabolic dysfunction, loss of calcium homeosta-
sis and fibrosis, suggesting that they may have utility as biomarkers for these specific features of DMD 
pathology. Future work will measure these biomarkers in larger patient cohorts, longitudinal studies, in 
patients treated with experimental therapies (e.g. exon skipping), and investigate the mechanisms which 
lead to secretion or leakage of these proteins from dystrophic muscle.
Methods
Animal Samples. All animal experimentation procedures were authorised and approved by the 
University of Oxford ethics committee and UK Home Office (project licence 30/2907) in accordance 
with the Animals (Scientific Procedures) Act 1986. 14 week old male C57/Bl10 and C57/Bl10ScSn-
Dmdmdx/J (mdx) mice (n = 8) were sacrificed and blood was collected from the jugular vein using 
Microvette CB300 serum collection tubes (Sarstedt, Leicester, UK). Whole blood was allowed to clot 
on ice and then spun for 5 minutes at 10,000 g. 75 μ l aliquots of serum were stored at − 80 °C prior 
to analysis. 12 week old male mdx mice (n = 8) were administrated with a single dose of 12.5 mg/kg 
Pip6a-PMO conjugate prepared in a sterile saline solution via tail vein injection. Animals were sac-
rificed at 14 weeks of age and serum was harvested as described above. Pip6a-PMO consists of a 
PMO (5′ -GGCCAAACCTCGGCTTACCTGAAAT) moiety chemically conjugated to an arginine-rich 
cell-penetrating peptide (Ac-RXRRBRRXR YQFLI RXRBRXRB-OH, where X is aminohexanoyl and B 
is β -alanine) and was synthesised and administered to the mice as described previously1,12.
Human Samples. Serum samples from Duchenne Muscular Dystrophy (DMD), Becker Muscular 
Dystrophy (BMD) and FacioScapuloHumeral muscular Dystrophy (FSHD) patients were obtained from 
Newcastle University through the MRC Centre for Neuromuscular Diseases Biobank. Serum samples 
from healthy individuals were obtained from Newcastle University (as above, n = 5) or collected from 
volunteers at the University of Oxford (n = 13). All samples were collected according to standard oper-
ating procedures applied at both locations. Collection of samples from patients and their use in research 
have been ethically approved by the National Research Ethics Service (NRES) Committee North East 
– Newcastle and North Tyneside 1 in accordance with the Helsinki Declaration. Informed consent was 
obtained from all subjects.
SOMAscan Serum Proteomics. Serum proteomics profiling was performed on the SOMAscan 
platform at SomaLogic, Inc. (Boulder, CO, USA). The SOMAscan platform measures the abundance 
of 1,129 target proteins, each of which is targeted by a unique SOMAmer reagent. Each SOMAmer 
consists of the protein binding aptamer component developed by SELEX (Systematic evolution of lig-
ands by exponential enrichment), a photo-cleavable biotin moiety for the initial SOMAmer-protein 
complex capture step, and a Cyanine3 fluorophore for the purposes of detection and quantification. 
Three dilutions (0.5%, 2% and 5%) were prepared for each sample. Each sample dilution was separately 
mixed with a set of SOMAmer reagents that were immobilised on streptavidin-coated beads. Beads were 
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washed to reduce non-specific protein binding. Proteins that remain captured on the SOMAmer-beads 
were biotinylated using NHS-PEO4-Biotin. After the labeling reaction, the beads are exposed to an 
anionic competitor solution that prevents non-specific interactions from reforming after they are dis-
rupted19. Biotinylated-protein-SOMAmer complexes were released from the beads using ultraviolet light 
to cleave the photo-cleavable linker contained within the SOMAmer component. Eluates (containing 
SOMAmer-protein complexes and free SOMAmers) were incubated with streptavidin-coated beads for 
a second time to precipitate biotinylated-protein-SOMAmer complexes. Free SOMAmer reagents were 
removed by subsequent washing of the beads. Finally, protein-SOMAmer complexes were eluted using 
denaturing conditions and the nucleic acid (SOMAmer) component quantified by hybridization to cus-
tom DNA microarrays. Note: For convenience human Entrez gene identifiers are used to describe output 
from the SOMAscan analysis. The complete SOMAscan dataset is provided in Supplementary File S1.
ELISA. Selected candidate proteins were validated using sandwich enzyme immunoassay. ELISA kits 
were purchased from antibodies-online (Aachen, Germany) and assay IDs are listed in Supplementary 
Table S2. Whenever possible, sera of the animals used for the SOMAscan screen was used. Due to lim-
ited amount of sample, additional age- and sex-matched animals were included in the study so that each 
group consisted of eight samples. ELISAs were performed according to manufacturer’s instructions and 
the serum was diluted to fall within the linear range of each respective assay. Sample concentrations 
were extrapolated with GraphPad Prism 5 (GraphPad Software Inc, La Jolla, CA) using fourth-order 
polynomial data fit of the standard curves.
Statistical Analysis. SOMAscan data were analysed using the SOMAsuite analysis software to per-
form Mann-Whitney U test (two-sided) and Kruskal-Wallis one-way ANOVA. Non-parametric anal-
yses were used as SOMAscan data were determined to not be normally distributed as determined by 
Shapiro-Wilk test (GraphPad Prism 5). Hierarchical clustering and heatmap visualization was performed 
using MeV (Multiple Experiment Viewer (The Institute for Genomic Research, Rockville, MD, USA)40. 
Principal component analysis was performed in R version 3.2. Additional statistical functions were per-
formed in GraphPad Prism 5: one-way ANOVA, Bonferroni post hoc test, Pearson/Spearman correlation, 
linear regression and ROC curve analysis.
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